RESUMEN
The OX-40 protein was selectively upregulated on encephalitogenic myelin basic protein (MBP)-specific T cells at the site of inflammation during the onset of experimental autoimmune encephalomyelitis (EAE). An OX-40 immunotoxin was used to target and eliminate MBP-specific T cells within the central nervous system without affecting peripheral T cells. When injected in vivo, the OX-40 immunotoxin bound exclusively to myelin-reactive T cells isolated from the CNS, which resulted in amelioration of EAE. Expression of the human OX-40 antigen was also found in peripheral blood of patients with acute graft-versus-host disease and the synovia of patients with rheumatoid arthritis during active disease. The unique expression of the OX-40 molecule may provide a novel therapeutic strategy for eliminating autoreactive CD4+T cells that does not require prior knowledge of the pathogenic autoantigen.
Asunto(s)
Artritis Reumatoide/sangre , Linfocitos T CD4-Positivos/patología , Encefalomielitis Autoinmune Experimental/inmunología , Inmunotoxinas/administración & dosificación , Proteína Básica de Mielina/inmunología , Receptores del Factor de Necrosis Tumoral , Ricina/administración & dosificación , Miembro 7 de la Superfamilia de Receptores de Factores de Necrosis Tumoral/inmunología , Animales , Artritis Reumatoide/inmunología , Linfocitos T CD4-Positivos/inmunología , Separación Celular , Encefalomielitis Autoinmune Experimental/metabolismo , Encefalomielitis Autoinmune Experimental/patología , Humanos , Ratas , Ratas Endogámicas Lew , Receptores OX40 , Subgrupos de Linfocitos T/inmunología , Miembro 7 de la Superfamilia de Receptores de Factores de Necrosis Tumoral/sangreRESUMEN
We have previously demonstrated that thyromimetics stimulate oligodendrocyte precursor cell differentiation and promote remyelination in murine demyelination models. We investigated whether a thyroid receptor-beta selective thyromimetic, sobetirome (Sob), and its CNS-targeted prodrug, Sob-AM2, could prevent myelin and axonal degeneration in experimental autoimmune encephalomyelitis (EAE). Compared to controls, EAE mice receiving triiodothyronine (T3, 0.4 mg/kg), Sob (5 mg/kg) or Sob-AM2 (5 mg/kg) had reduced clinical disease and, within the spinal cord, less tissue damage, more normally myelinated axons, fewer degenerating axons and more oligodendrocytes. T3 and Sob also protected cultured oligodendrocytes against cell death. Thyromimetics thus might protect against oligodendrocyte death, demyelination and axonal degeneration as well as stimulate remyelination in multiple sclerosis.
Asunto(s)
Acetatos/farmacología , Encefalomielitis Autoinmune Experimental/patología , Vaina de Mielina/efectos de los fármacos , Oligodendroglía/efectos de los fármacos , Fenoles/farmacología , Triyodotironina/farmacología , Animales , Enfermedades Desmielinizantes/patología , Femenino , Ratones , Ratones Endogámicos C57BL , Degeneración Nerviosa/patología , Profármacos/farmacologíaRESUMEN
Fatigue: Take Control is a novel program to teach fatigue management to people with multiple sclerosis (MS) following recommendations in the Fatigue and Multiple Sclerosis guideline. Fatigue: Take Control includes six 2-hour group sessions with DVD viewing, discussion and homework and accompanying participant and leader workbooks. While many people have participated in Fatigue: Take Control programs, its efficacy has not been determined. The objective of this study was to determine whether participation in Fatigue: Take Control reduces fatigue and increases self-efficacy in people with MS. Thirty participants were randomly assigned to a group who immediately participated in the program (FTC) or a wait-list group (WL). The primary outcome was the Modified Fatigue Impact Scale (MFIS) and secondary outcomes were the Multiple Sclerosis Self-Efficacy Scale (MSSE) and the Fatigue Severity Scale (FSS). The MFIS was administered on 10 occasions. Other measures were administered on four occasions. A mixed model tested the effects using all observations. Compared with the WL, the FTC group had significantly more improvement on the MFIS [F(1, 269) = 7.079, p = 0.008] and the MSSE [F(1, 111) = 5.636, p = 0.019]. No significant effect was found for the FSS. Across all visits, fatigue was significantly lower and self-efficacy was significantly higher for the FTC group compared with the WL group. This pilot study demonstrated significant effects in fatigue and self-efficacy among subjects taking the Fatigue: Take Control program, suggesting that this comprehensive program based on the Fatigue and Multiple Sclerosis guideline may be beneficial in MS.
Asunto(s)
Fatiga/terapia , Esclerosis Múltiple/complicaciones , Educación del Paciente como Asunto , Autoeficacia , Fatiga/complicaciones , Humanos , Proyectos Piloto , Evaluación de Programas y Proyectos de Salud , Índice de Severidad de la Enfermedad , Encuestas y Cuestionarios , Resultado del TratamientoRESUMEN
The polyneuropathy, organomegaly, edema, monoclonal protein, and skin changes (POEMS) syndrome is a multisystem disorder of unknown etiology. Neurologic manifestations include polyneuropathy, optic disk edema, and intracranial hypertension. We studied a patient with POEMS syndrome who had an infiltrative orbitopathy.
Asunto(s)
Enfermedades Orbitales/complicaciones , Papiledema/complicaciones , Femenino , Humanos , Persona de Mediana Edad , Enfermedades Orbitales/diagnóstico por imagen , Papiledema/diagnóstico por imagen , Polineuropatías/complicaciones , Síndrome , Tomografía Computarizada por Rayos XRESUMEN
We studied five patients who had acute cerebral infarctions 5 weeks to 6 months after herpes zoster ophthalmicus (HZO). All had infarcts of the cerebral hemisphere ipsilateral to the HZO, and one also had a cerebellar infarct. Cerebral arteriography in one patient disclosed narrowing of the middle cerebral artery, occlusion of the anterior cerebral artery ipsilateral to the HZO and narrowing of the opposite anterior cerebral artery. In another case, arteriography revealed occlusion of the distal internal carotid artery on the side of the HZO.
Asunto(s)
Infarto Cerebral/diagnóstico , Herpes Zóster Oftálmico/complicaciones , Adolescente , Adulto , Anciano , Angiografía Cerebral , Infarto Cerebral/etiología , Niño , Femenino , Lateralidad Funcional , Humanos , Masculino , Persona de Mediana EdadRESUMEN
BACKGROUND AND OBJECTIVE: A phase III double-blind, placebo-controlled clinical trial demonstrated that interferon beta-1a (IFN beta-1a) (Avonex, Biogen) significantly delayed progression of disability in relapsing MS patients. The primary clinical outcome was time from study entry until disability progression, defined as > or = 1.0 point worsening from baseline Kurtzke Expanded Disability Status Scale (EDSS) score persisting for at least two consecutive scheduled visits separated by 6 months. The objective of this study was to examine the magnitude of benefit on EDSS and its clinical significance. METHODS: Post hoc analyses related to disability outcomes using data collected during the double-blind, placebo-controlled phase III clinical trial. RESULTS: (1) Clinical efficacy related to disability did not depend on the definition of disability progression. A significant benefit in favor of IFN beta-1a was observed when > or = 2.0 point worsening from baseline EDSS was required or when worsening was required to persist for > or = 1.0 year. (2) Placebo recipients who reached the primary clinical outcome worsened by a larger amount from baseline EDSS than did IFN beta-1a recipients who reached the primary study outcome. (3) Significantly fewer IFN beta-1a recipients progressed to EDSS milestones of 4.0 (relatively severe impairment) or 6.0 (unilateral assistance needed to walk). (4) Cox proportional hazards models demonstrated that the only baseline characteristic strongly correlated with longer time to disability progression was IFN beta-1a treatment. CONCLUSIONS: The primary clinical outcome for the IFN beta-1a clinical trial underestimated clinical benefits of treatment. Results in this report demonstrate that IFN beta-1a treatment is associated with robust, clinically important beneficial effects on disability progression in relapsing MS patients.
Asunto(s)
Personas con Discapacidad , Interferón beta/uso terapéutico , Esclerosis Múltiple/terapia , Sistema Nervioso/fisiopatología , Adolescente , Adulto , Progresión de la Enfermedad , Método Doble Ciego , Humanos , Interferón beta-1a , Persona de Mediana Edad , Esclerosis Múltiple/fisiopatología , Recurrencia , Análisis de SupervivenciaRESUMEN
Myelin basic protein (BP)-specific T lymphocyte cell lines were selected from the lymph nodes (LN) of BP-immunized, H-2d, CXJ-1 mice prior to the onset of clinical disease. These CD4+ T cells induced severe acute experimental autoimmune encephalomyelitis (EAE) in MHC-compatible (H-2d), lymphocyte-deficient (SCID) mice (C.B-17scid/scid). The incidence of disease was much higher in immunodeficient SCID mice (71%) than in syngeneic immunocompetent CXJ-1 mice (5%). SCID mice with EAE had an acute progressive paralytic disease with inflammation and myelin loss detected in the spinal cord. Eighty-six percent (12/14) of mice followed for more than 2 weeks had 1 or more relapses of EAE. These results demonstrate that clinical remission and relapse of EAE can be induced by the single adoptive transfer of a LN-derived BP-specific T cell line in the absence of host-derived effector and regulatory lymphocytes. Furthermore, the data demonstrate that the pathogenic potential of BP-specific T cells is greater in lymphocyte-deficient SCID mice compared with immunocompetent mice, suggesting that autoreactive T cells are controlled by potent inhibitory mechanisms associated with regulatory lymphocytes. These results are relevant to mechanisms of disease remission and relapse mediated by lymphocytes involved in paralytic inflammatory diseases such as multiple sclerosis (MS).
Asunto(s)
Linfocitos T CD4-Positivos/inmunología , Encefalomielitis Autoinmune Experimental/inmunología , Epítopos , Ratones SCID/inmunología , Proteína Básica de Mielina/inmunología , Animales , Linfocitos T CD4-Positivos/química , Linfocitos T CD4-Positivos/citología , Linfocitos T CD8-positivos/química , Linfocitos T CD8-positivos/citología , Linfocitos T CD8-positivos/inmunología , Línea Celular , Trasplante de Células , Enfermedad Crónica , Modelos Animales de Enfermedad , Encefalomielitis Autoinmune Experimental/patología , Femenino , Inmunofenotipificación , Antígenos Comunes de Leucocito/análisis , Antígeno de Macrófago-1/análisis , Ratones , Recurrencia , Médula Espinal/química , Médula Espinal/inmunología , VacunaciónRESUMEN
To investigate the role of anti-myelin antibodies in chronic relapsing experimental allergic encephalomyelitis (CR-EAE), sera from SJL/J mice with CR-EAE actively induced by inoculation with spinal cord homogenate in complete Freund's adjuvant (CFA) were compared with sera from mice to whom CR-EAE was passively transferred by lymph node cells (LNC) stimulated with myelin basic protein (BP). Sera were obtained serially from mice during both remissions and relapses of disease and were evaluated for the presence of anti-myelin antibodies using an avidin-biotin-immunoperoxidase technique. Four of six mice with CR-EAE induced with cord-CFA were positive for anti-myelin antibodies 15-124 days after inoculation, with 16 of 18 sera positive in these four mice. Two mice inoculated with cord-CFA did not have detectable serum anti-myelin antibodies, despite a clinical and histopathological picture indistinguishable from the antibody-positive mice. None of seven mice with CR-EAE passively transferred by BP-stimulated LNC had detectable anti-myelin antibodies in 30 sera obtained 7-141 days after cell transfer. We conclude that serum anti-myelin antibodies probably do not play a significant role in the pathogenesis of CR-EAE in SJL/J mice.
Asunto(s)
Autoanticuerpos/análisis , Encefalomielitis Autoinmune Experimental/inmunología , Proteína Básica de Mielina/inmunología , Animales , Autoanticuerpos/fisiología , Enfermedad Crónica , Encefalomielitis Autoinmune Experimental/etiología , Encefalomielitis Autoinmune Experimental/patología , Femenino , Inmunización Pasiva , Técnicas para Inmunoenzimas , Ratones , Ratones Endogámicos , Recurrencia , Médula Espinal/inmunologíaRESUMEN
This is the first description of acute demyelinating experimental autoimmune encephalomyelitis (EAE) induced in rats by myelin basic protein (BP)-specific T lymphocytes without the administration of demyelinating antibodies. BP-specific T cell lines were selected from inbred Buffalo-strain rats (Rt-1b) following techniques used to develop similar lines from Lewis rats (Rt-1l). Unlike those of Lewis rats, the spinal cords of Buffalo rats with T cell line-mediated EAE had prominent perivascular demyelination associated with mononuclear inflammation. Like Lewis rat lines. Buffalo rat BP-specific T cell lines transferred acute, non-relapsing EAE into syngeneic recipients, demonstrating that demyelination in passive acute EAE can occur without subsequent clinical relapses.
Asunto(s)
Enfermedades Autoinmunes/etiología , Enfermedades Desmielinizantes/etiología , Encefalomielitis/etiología , Proteína Básica de Mielina/inmunología , Linfocitos T/inmunología , Animales , Línea Celular , Encefalomielitis/patología , Femenino , Cobayas , Hipersensibilidad Tardía , Inmunoterapia Adoptiva , Ratas , Ratas Endogámicas BUF , Ratas Endogámicas Lew , Médula Espinal/patologíaRESUMEN
Relapsing experimental autoimmune encephalomyelitis (EAE) was induced in Lewis rats by intraperitoneal immunization with guinea pig whole central nervous system tissue. Basic protein (BP)-specific T cell lines selected from rats with relapsing EAE proliferated in response to BP, the 44-89 peptidase fragment of BP and the synthetic peptide, S72-89, as did lines selected from rats with non-relapsing EAE induced by immunization with guinea pig BP. BP-specific T cell lines selected from rats with relapsing EAE transferred acute but not relapsing EAE. BP-specific T cell lines selected from Lewis rats with relapsing EAE appear not to differ from those selected from rats with non-relapsing EAE.
Asunto(s)
Encefalomielitis Autoinmune Experimental/inmunología , Proteína Básica de Mielina/inmunología , Linfocitos T/inmunología , Animales , Línea Celular , Femenino , Ratas , Ratas Endogámicas Lew , Ratas EndogámicasRESUMEN
T cell lines were selected from basic protein (BP)-immunized SJL/J mice using synthetic peptides encompassing the major SJL/J encephalitogenic determinant. Synthetic peptide-derived T cell lines proliferated in response to BP, the 89-169 peptidase fragment of BP and the synthetic peptides, pM87-99, pM90-99 and pM91-99. These lines transferred a demyelinating and chronic relapsing form of experimental autoimmune encephalomyelitis (EAE) into naive mice, and EAE induced by synthetic peptide-derived lines was more severe than that induced by whole BP-derived lines. This study demonstrates that T cell lines selected with synthetic peptides are encephalitogenic in SJL/J mice and offers an improved means for selecting SJL/J encephalitogenic T cell lines.
Asunto(s)
Encefalitis/inmunología , Péptidos/inmunología , Linfocitos T/inmunología , Animales , División Celular , Línea Celular , Encefalitis/patología , Ratones , Ratones Endogámicos , Proteína Básica de Mielina/inmunología , Fragmentos de Péptidos/inmunología , Péptidos/síntesis química , Linfocitos T/citología , Linfocitos T/fisiologíaRESUMEN
Previously, we constructed chimeras by injecting hematopoietic cells from experimental autoimmune encephalomyelitis (EAE)-susceptible SJL (H-2s) strain mice into severe combined immunodeficient (SCID) C.B-17scid/scid (H-2d) mice. These SCID mouse-SJL mouse hematopoietic cell chimeras developed passive EAE following adoptive transfer of PLP S139-151-specific SJL T lymphocyte line cells, but were resistant to active EAE induced by primary immunization with PLP S139-151. In order to gain an understanding of the encephalitogenic potential of transplanted hematopoietic progenitors in SCID mouse-SJL mouse chimeras, we attempted to induce EAE in hematopoietic chimeras constructed with or without an additional SJL fetal thymus implant. Chimeras with the thymus implant were susceptible to passive and active EAE while chimeras without the thymus implant were susceptible to passive but not active EAE. Encephalitogenic, CD4+, TCR+ T lymphocytes were selected in vitro from PLP S139-151-immunized, thymus-implanted chimeras. These results showed that hematopoietic SJL progenitors developed into antigen-presenting accessory cells and immunocompetent encephalitogenic T lymphocytes following transplantation into SCID mice. The development of primary immune reactivity depended on a fetal thymus implant for expression in SCID mouse-SJL mouse chimeras.
Asunto(s)
Encefalomielitis Autoinmune Experimental/etiología , Trasplante de Células Madre Hematopoyéticas , Linfocitos T/inmunología , Secuencia de Aminoácidos , Animales , Secuencia de Bases , Línea Celular , Quimera , Humanos , Inmunoterapia Adoptiva , Ratones , Ratones SCID , Datos de Secuencia Molecular , Proteínas de la Mielina/inmunología , Proteína Proteolipídica de la MielinaRESUMEN
T cell sensitization to two myelin components, myelin basic protein (MBP) and myelin proteolipid protein (PLP), may be important to the pathogenesis of multiple sclerosis (MS). Using the limiting dilution assay, we demonstrated that the blood of MS patients had an increased frequency of MBP-reactive T cells compared with normal subjects and patients with other neurological diseases (OND) and rheumatoid arthritis. There was no difference in T cell frequency to a synthetic peptide, PLP139-151, or Herpes simplex virus. Within cerebrospinal fluid (CSF), 37% of IL-2/IL-4-reactive T cell isolates from MS patients responded either to MBP or PLP139-151 while only 5% of similar isolates from OND patients responded to these myelin antigens. The mean relative frequency of MBP-reactive T cells within CSF from MS patients was significantly higher than that of OND patients (22 x 10(-5) cells versus 1 x 10(-5) cells) and was similar to that of MBP reactive T cells within the central nervous system of rats with experimental autoimmune encephalomyelitis. These results lend new support to the hypothesis that myelin-reactive T cells mediate disease in MS.
Asunto(s)
Células Sanguíneas/inmunología , Líquido Cefalorraquídeo/inmunología , Esclerosis Múltiple/inmunología , Proteína Básica de Mielina/inmunología , Proteínas de la Mielina/inmunología , Linfocitos T/inmunología , Secuencia de Aminoácidos , Aminoácidos/química , Aminoácidos/farmacología , Líquido Cefalorraquídeo/citología , Humanos , Técnicas de Dilución del Indicador , Interleucina-2/líquido cefalorraquídeo , Interleucina-4/líquido cefalorraquídeo , Recuento de Leucocitos , Datos de Secuencia Molecular , Esclerosis Múltiple/sangre , Esclerosis Múltiple/líquido cefalorraquídeo , Proteína Proteolipídica de la MielinaRESUMEN
Interleukin-7 has demonstrated potent enhancing effects on the growth and differentiation of several immature cell types, including thymocytes, and on survival of resting and antigen activated T cells. In this study, we evaluated the effects of IL-7 on post-thymic antigen-specific T cells from human blood. IL-7 was found to enhance proliferation responses and IFN-gamma secretion of myelin or recall Ag-specific Th1 cells through the selective up-regulation of the IL-2Ralpha and gamma but not beta chains in both an Ag-dependent and Ag-independent manner, but did not affect monocytes, B cells, or NK cells. These functions of IL-7 enhanced the detection of Th1 but not Th2 cell frequency by >2.5 fold, and promoted selection of Ag-specific Th1 cells by the limiting dilution method. Moreover, IL-7 pretreatment conferred increased resistance of CD4+ T cells to CD8+ cell lysis. These studies demonstrate that IL-7 promotes the growth and survival of circulating Ag-specific human Th1 cells through a mechanism that probably involves the gammac common receptor for IL-2 family members that includes IL-7.
Asunto(s)
Linfocitos T CD8-positivos/metabolismo , Interleucina-7/farmacología , Receptores de Interleucina-2/metabolismo , Antígenos CD19/inmunología , Antígenos CD19/metabolismo , Antígenos CD11/inmunología , Antígenos CD11/metabolismo , Linfocitos T CD4-Positivos/química , Linfocitos T CD4-Positivos/inmunología , Linfocitos T CD4-Positivos/metabolismo , Antígeno CD56/inmunología , Antígeno CD56/metabolismo , Linfocitos T CD8-positivos/química , Linfocitos T CD8-positivos/citología , División Celular/inmunología , Supervivencia Celular/inmunología , Células Clonales , Humanos , Inmunofenotipificación , Interferón gamma/inmunología , Interferón gamma/metabolismo , Interleucina-2/farmacología , Receptores de Interleucina-2/análisis , Receptores de Interleucina-2/inmunología , Timo/citologíaRESUMEN
BACKGROUND AND OBJECTIVE: This report provides results of CSF analyses done in a subset of relapsing remitting MS patients participating in a placebo-controlled, double-blind, phase III clinical trial of IFNbeta-Studies supported by the National Multiple Sclerosis Society (grants RG2019, RG2827),a (Avonex , Biogen). The clinical trial demonstrated that IFNbeta-1a treatment resulted in significantly reduced disability progression, annual relapse rate, and new brain lesions visualized by cranial magnetic resonance imaging. The objectives of the current study were to determine: (a) whether CSF abnormalities in MS patients correlated with disease or MRI characteristics, and (b) effects of IFNbeta-1a therapy on these CSF abnormalities. METHODS: CSF was analyzed from 262 (87%) of the 301 study subjects at entry into the clinical trial, and a second CSF sample was analyzed from 137 of these 262 subjects after 2 years of therapy. CSF cell counts, oligoclonal bands (OCB), IgG index, and free kappa light chains were measured using standard assays. Baseline CSF results were compared with demographic, disease, and MRI parameters. Differences in on-study relapse rate, gadolinium enhancement, and EDSS change according to baseline CSF status was used to determine the predictive value of CSF for subsequent clinical and MRI disease activity. Change in CSF parameters after 104 weeks were used to determine the effects of treatment. RESULTS: (1) At study baseline, 37% of the subjects had abnormal CSF WBC counts, 61% had abnormal levels of CSF free kappa light chains, 84% had abnormal IgG index values, and 90% were positive for OCB. (2) Baseline IgG index, kappa light chains, and OCB showed weakly positive, statistically significant correlations with Gd-enhanced lesion volume and T2 lesion volume. WBC showed a statistically significant correlation with Gd-enhancing lesion volume but was uncorrelated with T2 lesion volume. (3) There was an associated between baseline CSF WBC counts and on-study clinical and MRI disease activity in placebo recipients. (4) IFNbeta-1a treatment resulted in significantly reduced CSF WBC counts, but there was no treatment-related change in CSF IgG index, kappa light chains, or OCB, which remained relatively stable over time in both patient groups. CONCLUSIONS: The current study documents significant reductions in CSF WBC counts in patients treated with IFNbeta-1a for 104 weeks. This finding is considered relevant to the therapeutic response, since CSF WBC counts were found to be positively correlated with subsequent clinical and MRI disease activity in placebo-treated relapsing MS patients.
Asunto(s)
Adyuvantes Inmunológicos/administración & dosificación , Interferón beta/administración & dosificación , Esclerosis Múltiple/líquido cefalorraquídeo , Esclerosis Múltiple/tratamiento farmacológico , Adyuvantes Inmunológicos/efectos adversos , Adulto , Líquido Cefalorraquídeo/citología , Líquido Cefalorraquídeo/inmunología , Método Doble Ciego , Femenino , Humanos , Inmunoglobulina G/líquido cefalorraquídeo , Cadenas kappa de Inmunoglobulina/líquido cefalorraquídeo , Inmunoglobulinas/líquido cefalorraquídeo , Interferón beta-1a , Interferón beta/efectos adversos , Recuento de Leucocitos , Masculino , Persona de Mediana Edad , Esclerosis Múltiple/inmunología , Bandas Oligoclonales , RecurrenciaRESUMEN
Four antisera to the ganglioside GM1 were tested for effects on myelin and axons when applied to mouse spinal cord-dorsal root ganglia explant cultures. None of the antisera to GM1 caused myelination inhibition or demyelination, while an antiserum to galactocerebroside caused both. Antisera to GM1 did not inhibit axonal outgrowth or destroy mature outgrowth zone axons, while an antiserum to a rat brain axolemma-enriched fraction did both. These results suggest that antibodies to GM1 do not have significant anti-myelin or anti-axon activity.
Asunto(s)
Axones/fisiología , Gangliósido G(M1)/fisiología , Sueros Inmunes/farmacología , Vaina de Mielina/fisiología , Médula Espinal/fisiología , Animales , Axones/efectos de los fármacos , Células Cultivadas , Gangliósido G(M1)/inmunología , Ratones , Vaina de Mielina/efectos de los fármacos , Médula Espinal/citología , Médula Espinal/efectos de los fármacosRESUMEN
Antisera prepared to an axolemma-enriched fraction derived from rat brain inhibited neurite outgrowth and destroyed mature axons in spinal cord-dorsal root ganglia cultures. Similar antibody-mediated anti-axon effects may be important in some diseases of the human nervous system.
Asunto(s)
Antígenos de Superficie/inmunología , Autoanticuerpos , Enfermedades Autoinmunes , Axones/inmunología , Enfermedades del Sistema Nervioso/etiología , Animales , Técnicas de Cultivo , Feto , Ganglios Espinales/inmunología , Ratones , Médula Espinal/inmunologíaRESUMEN
Synthetic peptides corresponding to germline TCR V beta 8.2 sequences overexpressed by Lewis rat encephalitogenic T cells are effective in the prevention and treatment of autoimmune encephalomyelitis (EAE). In evaluating optimal conditions for identifying disease-relevant target V beta genes, we found that the biased expression of V beta 8.2 was most pronounced in the CNS among activated, IL-2 responsive T cells, but was weakly reflected in the cerebrospinal fluid. Evaluation of basic protein reactive T cells from patients with multiple sclerosis revealed biased expression of V beta 5.2 and to a lesser degree, V beta 6.1. Treatment of 11 MS patients with synthetic TCR V beta 5.2 and V beta 6.1 CDR2 peptides boosted the frequency of anti-TCR reactive T cells in a majority of patients, without compromising recall immunity or causing side effects. TCR peptides may be useful in the treatment of human autoimmune diseases, providing that disease-relevant V genes can be identified.
Asunto(s)
Encefalomielitis Autoinmune Experimental/terapia , Esclerosis Múltiple/terapia , Receptores de Antígenos de Linfocitos T alfa-beta/inmunología , Animales , Artritis Reumatoide/etiología , Encefalomielitis Autoinmune Experimental/inmunología , Humanos , Inmunoterapia , Ratones , Esclerosis Múltiple/inmunología , Proteína Básica de Mielina/inmunología , Péptidos/síntesis química , Péptidos/inmunología , Péptidos/uso terapéutico , Ratas , Ratas Endogámicas Lew , Receptores de Antígenos de Linfocitos T alfa-beta/genéticaRESUMEN
Few epidemiological studies have been conducted that have incorporated clinical evaluations of Gulf War veterans with unexplained health symptoms and healthy controls. We conducted a mail survey of 2022 Gulf War veterans residing in the northwest United States and clinical examinations on a subset of 443 responders who seemed to have unexplained health symptoms or were healthy. Few clinical differences were found between cases and controls. The most frequent unexplained symptoms were cognitive/psychological, but significant overlap existed with musculoskeletal and fatigue symptoms. Over half of the veterans with unexplained musculoskeletal pain met the criteria for fibromyalgia, and a significant portion of the veterans with unexplained fatigue met the criteria for chronic fatigue syndrome. Similarities were found in the clinical interpretation of unexplained illness in this population and statistical factor analysis performed by this study group and others.